Carperitide is under clinical development by Daiichi Sankyo and currently in Phase II for Contrast Induced Nephropathy. According to GlobalData, Phase II drugs for Contrast Induced Nephropathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Carperitide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Carperitide overview
Carperitide (Hanp, SUN 4936h) is the alpha-human atrial natriuretic peptide produced by recombinant technology. It is formulated as injectable powder for solution for intravenous route of administration. Hanp is indicated in for treatment of acute heart failure (including acute exacerbation of chronic heart failure).
The drug candidate is under development for contrast-induced nephropathy. It was also under development for acute heart failure in EU and U.S. and for acute respiratory distress syndrome.
Daiichi Sankyo overview
Daiichi Sankyo is a global healthcare company that focuses on the discovery, development, and delivery of innovative medical solutions. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
For a complete picture of Carperitide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
